Core Viewpoint - BioHarvest Sciences Inc. has approved long-term incentive awards to align employee interests with shareholder value and support growth across its business segments [1][3]. Group 1: Long-term Incentive Awards - The awards include 516,812 stock options and 264,121 restricted share units (RSUs), with stock options valid for 10 years and both options and RSUs vesting quarterly over three years starting March 13, 2026 [2]. - The equity-based incentives are designed to reward and retain top talent while minimizing immediate cash impact on the company [3]. Group 2: Business Strategy and Growth - BioHarvest is focused on expanding its proprietary Botanical Synthesis platform in consumer nutraceutical products and its contract development and manufacturing organization (CDMO) division [4]. - The company emphasizes the importance of attracting and retaining exceptional talent as a key driver of sustainable growth and shareholder returns [4]. Group 3: Company Overview - BioHarvest Sciences Inc. is a leader in Botanical Synthesis, utilizing its patented technology to produce plant-based compounds without growing the underlying plants [5]. - The company aims to develop science-based therapeutic solutions in two major business verticals: as a CDMO and as a creator of proprietary nutraceutical health products [5].

Core Insights - BioHarvest Sciences Inc. will host a Virtual Investor Webinar on September 10, 2025, at 1:00 PM ET to provide updates on corporate initiatives and future plans [1][2] - CEO Ilan Sobel will discuss new capability-building initiatives and the company's 'Big Bets' for the second half of 2025, including the Health Pros program and hydration products [2] - The webinar will include a question-and-answer session for participants, emphasizing the company's focus on profitable growth and long-term shareholder value [2] Company Overview - BioHarvest Sciences Inc. is a leader in Botanical Synthesis, utilizing patented technology to grow active ingredients in plants without cultivating the plants themselves [4] - The company operates in two main business verticals: as a contract development and production organization (CDMO) for complex molecules and as a creator of proprietary nutraceutical health and wellness products [4] - BioHarvest aims to develop science-based and clinically proven therapeutic solutions, enhancing its product offerings and expanding its CDMO pipeline [4]

Core Insights - BioHarvest Sciences Inc. has successfully progressed its CDMO contract with a Nasdaq-listed pharmaceutical company from Stage 1 to Stage 2, validating its Botanical Synthesis platform for developing active pharmaceutical compounds [1][4] Group 1: Contract Development and Manufacturing Organization (CDMO) Progress - Stage 1 of the contract, initiated in early 2024, involved sourcing plants to develop a compound for an approved drug product, which has now been completed successfully [2] - The successful completion of Stage 1 indicates that the research team isolated and multiplied the target plant cells using the proprietary Botanical Synthesis platform [2] - Stage 2 will focus on delivering sufficient biomass for testing and developing optimal growing conditions, leading to small and medium-scale production and eventually commercial volume production [3] Group 2: Company Statements and Future Outlook - The CEO of BioHarvest expressed excitement about advancing to Stage 2, highlighting the milestone as a validation of the platform's versatility and its potential to provide cost-effective alternatives to traditional sourcing methods [4] - The Chairman of the CDMO Division noted that Stage 1 carried the highest technical risk, and its successful completion demonstrates the platform's capability to address a wide range of molecule families, with Stage 2 expected to have a higher probability of success [4]